Show simple item record

dc.contributor.authorHaynes, BP
dc.contributor.authorSchuster, G
dc.contributor.authorBuus, R
dc.contributor.authorAlataki, A
dc.contributor.authorGinsburg, O
dc.contributor.authorQuang, LH
dc.contributor.authorHan, PT
dc.contributor.authorKhoa, PH
dc.contributor.authorVan Dinh, N
dc.contributor.authorVan To, T
dc.contributor.authorClemons, M
dc.contributor.authorHolcombe, C
dc.contributor.authorOsborne, C
dc.contributor.authorEvans, A
dc.contributor.authorSkene, A
dc.contributor.authorSibbering, M
dc.contributor.authorRogers, C
dc.contributor.authorLaws, S
dc.contributor.authorNoor, L
dc.contributor.authorCheang, MCU
dc.contributor.authorCleator, SJ
dc.contributor.authorSmith, IE
dc.contributor.authorDowsett, M
dc.identifier.citationBreast cancer research and treatment, 2021, 190 (2), pp. 295 - 305
dc.description.abstractPurpose Changes occur in the expression of oestrogen-regulated and proliferation-associated genes in oestrogen receptor (ER)-positive breast tumours during the menstrual cycle. We investigated if Oncotype® DX recurrence score (RS), Prosigna® (ROR) and EndoPredict® (EP/EPclin) prognostic tests, which include some of these genes, vary according to the time in the menstrual cycle when they are measured. Methods Pairs of test scores were derived from 30 ER-positive/human epidermal growth factor receptor-2-negative tumours sampled at two different points of the menstrual cycle. Menstrual cycle windows were prospectively defined as either W1 (days 1-6 and 27-35; low oestrogen and low progesterone) or W2 (days 7-26; high oestrogen and high or low progesterone). Results The invasion module score of RS was lower (- 10.9%; p = 0.098), whereas the ER (+ 16.6%; p = 0.046) and proliferation (+ 7.3%; p = 0.13) module scores were higher in W2. PGR expression was significantly increased in W2 (+ 81.4%; p = 0.0029). Despite this, mean scores were not significantly different between W1 and W2 for any of the tests and the two measurements showed high correlation (r = 0.72-0.93). However, variability between the two measurements led to tumours being assigned to different risk categories in the following proportion of cases: RS 22.7%, ROR 27.3%, EP 13.6% and EPclin 13.6%. Conclusion There are significant changes during the menstrual cycle in the expression of some of the genes and gene module scores comprising the RS, ROR and EP/EPclin scores. These did not affect any of the prognostic scores in a systematic fashion, but there was substantial variability in paired measurements.
dc.format.extent295 - 305
dc.subjectBreast Neoplasms
dc.subjectNeoplasm Recurrence, Local
dc.subjectReceptors, Estrogen
dc.subjectMenstrual Cycle
dc.titleImpact of the menstrual cycle on commercial prognostic gene signatures in oestrogen receptor-positive primary breast cancer.
dc.typeJournal Article
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBreast cancer research and treatment
pubs.notesNot known
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology/Endocrinology (hon.)
pubs.embargo.termsNot known
icr.researchteamClinical Trials & Statistics Unit
dc.contributor.icrauthorDowsett, Mitchen_US
dc.contributor.icrauthorCheang, Chonen_US

Files in this item


This item appears in the following collection(s)

Show simple item record
Except where otherwise noted, this item's license is described as